Mallinckrodt gave up further development of adrabetadex (VTS-270; HPBCD)
Mallinckrodt Pharmaceuticals has reached an agreement to divest and transfer the Investigational New Drug (IND) application for experimental drug adrabetadex
Tag: Niemann Pick Disease
Weakly acidic carboxy group-grafted β-cyclodextrin-threaded acid-degradable polyrotaxanes for modulating protein interaction and cellular internalization
To improve the therapeutic potential of β-cyclodextrin (β-CD)-threaded acid-degradable polyrotaxanes (β-CD PRXs) in cholesterol-related metabolic disorders, the effect of carboxylation
Cyclo Therapeutics Announces Design of Pivotal Phase 3 Study Evaluating Trappsol® Cyclo™ in Niemann-Pick Type C1
Cyclo Therapeutics, Inc., a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and
Central nervous system delivery of molecules across the blood-brain barrier
Therapies targeting neurological conditions such as Alzheimer’s or Parkinson’s diseases are hampered by the presence of the blood-brain barrier (BBB).
Intracerebroventricular Treatment with 2-Hydroxypropyl-β-Cyclodextrin Decreased Cerebellar and Hepatic Glycoprotein Nonmetastatic Melanoma Protein B (GPNMB) Expression in Niemann–Pick Disease Type C Model Mice
Niemann–Pick disease type C (NPC) is a recessive hereditary disease caused by mutation of the NPC1 or NPC2 gene. It is characterized by abnormality
Why HPGCD is better for NPC treatment compared to HPBCD?
Niemann-Pick disease type C (NPC) is a lysosomal storage disorder with disrupted intracellular cholesterol trafficking. HP-β-CD is a cholesterol solubilizer
Cyclo Therapeutics Meets Primary Efficacy Endpoint in Phase 1/2 Trial from Intravenous Trappsol® Cyclo™ in Rare Disease Niemann-Pick Type C1 (NPC1)
100% of patients who completed the trial improved or remained stable, and 89% met the efficacy outcome measure of improvement
Cochlear spiral ganglion neuron degeneration following cyclodextrin-induced hearing loss
HPβCD as a treatment for Niemann-Pick Type C1 disease can reduce some debilitating symptoms and extend life span, but the
Cyclo Therapeutics Presents Positive Data from Clinical Development Program for Lead Candidate, Trappsol® Cyclo™, at WORLDSymposium 2021
Cyclo Therapeutics, Inc., a clinical stage biotechnology company developing cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C and
Cyclo Therapeutics Announces Pricing of $12.5 Million Public Offering
Transaction Includes Uplisting to Nasdaq and Reverse Stock Split Cyclo Therapeutics, Inc., a clinical stage biotechnology company developing a cyclodextrin